USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Pharmos Corporation
Address:
2 INNOVATION DR
Alachua, FL 32615
Phone:
(904) 462-1210
URL:
N/A
EIN:
N/A
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $545,331.00 10
SBIR Phase II $1,696,783.00 4

Award List:

CHELATING AGENTS

Award Year / Program / Phase:
1986 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
DOE
Principal Investigator:
Dr. efraim shek , PRINCIPAL INVESTIGATOR
Abstract:
Most chelating agents that are effective in decorportation radionuclides from patients exposed to them are not effective when administered orally. dtpa is an example of achelating agent which has to be given i.v. on a daily basis to remove effectively plutonium from the skeleton and other soft… More

ORAL DELIVERY OF A SUSTAINED ESTRADIOL DELIVERY SYSTEM

Award Year / Program / Phase:
1987 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Kerry S Estes Phd
Abstract:
N/a

IMPROVED DELIVERY OF ANTIVIRALS FOR CNS INFECTIONS

Award Year / Program / Phase:
1988 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
Human cytomegalovirus (hcmv) is a common and not usually serious infective agent. however, in the case of acquired immunodeficiency syndrome (aids) and other immuno-suppressedstates, hcmv is inordinately virulent and is even a major cause of death. recently, treatment of hcmv infections in… More

ORAL DELIVERY OF A SUSTAINED ESTRADIOL DELIVERY SYSTEM

Award Year / Program / Phase:
1988 / SBIR / Phase II
Award Amount:
$462,000.00
Agency:
HHS
Principal Investigator:
Kerry S Estes Phd
Abstract:
Studies are proposed to evaluate the feasibility of oral 17beta-estradiol (e2) administration using a novel redox system. this chemical delivery system (cds) is based on an interconversion of a lipophilic dihydropyridine to a hydrophilic pyridinium salt, analogous to the nadh nad+ coenzyme system.… More

PRODUCTION SYNTHESIS OF INSULIN-LIKE GROWTH FACTOR II SYNTHESIS OF IMPROVED DELIVERY FORMS OF ANTIVIRAL AGENTS

Award Year / Program / Phase:
1988 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
New methods are needed which will allow for the routine production by solid phase synthesis of peptides of 60 to 70 amino acids in length on the 50 to 100 gram scale. currently, peptides can be made either by solid phase synthesis techniques on small scale (up to 5 gm) or by genetic engineering:… More

CROSS-AXIS COIL PLANET CENTRIFUGE CHROMATOGRAPH DESIGN AND SYNTHESIS OF BRAIN-SPECIFIC ANTIHERPETIC AGENTS

Award Year / Program / Phase:
1988 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

CROSS-AXIS COIL PLANET CENTRIFUGE CHROMATOGRAPH DESIGN AND SYNTHESIS OF BRAIN-SPECIFIC ANTIHERPETIC AGENTS

Award Year / Program / Phase:
1989 / SBIR / Phase II
Award Amount:
$416,005.00
Agency:
HHS
Principal Investigator:
Abstract:
A new countercurrent chromatography instrument, the cross-axis flow-through coil planet centrifuge is proposed for the preparative chromatography of peptides. this is an apparatus that separates substances according to their partitioning in a liquid-liquid equilibration system withoutthe use of a… More

IMPROVED THERAPY FOR CNS TOXOPLASMOSIS

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
Cerebral toxoplasmosis is the most common opportunistic disease affecting the brain of patients with acquired immunedeficiency syndrome (aids). sulfonamide treatment is initially effective in treating the infection, but the regimen often causes side effects that limit therapy, subsequently provoking… More

IMPROVED THERAPY FOR DEPRESSION

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Emil Pop
Abstract:
Depression is a heterogenous disease, covering a range of severity, qualities, and causes that affects an important portion of population. none of the available treatment modalities of depression, including electroconvulsive therapy and pharmacotherapy mainly by tricyclics and monoamine oxidase… More

DEVELOPMENT OF A NONSURFACTANT FORMULATION FOR INDUCING AGENTS

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$45,390.00
Agency:
HHS
Principal Investigator:
Wesley R Anderson
Abstract:
N/a

PARENTERAL FORMULATION FOR CARBAMAZEPINE

Award Year / Program / Phase:
1991 / SBIR / Phase I
Award Amount:
$49,941.00
Agency:
HHS
Principal Investigator:
Kerry Estes
Abstract:
N/a

DEVELOPMENT OF A NONSURFACTANT FORMULATION FOR INDUCING AGENTS

Award Year / Program / Phase:
1992 / SBIR / Phase II
Award Amount:
$318,778.00
Agency:
HHS
Principal Investigator:
Wesley R Anderson
Abstract:
Adverse reactions have been reported to occur after administration of compounds solubilized in aqueous vehicles. these side effects may be reduced or eliminated by combining the primary inducing agent, alfaxalone, with cyclodextrins, which have been shown to improve solubility and efficacy of other… More

PARENTERAL FORMULATION FOR CARBAMAZEPINE

Award Year / Program / Phase:
1992 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Kerry Estes
Abstract:
The favorable efficacy, toxicity and adverse side-effect profiles of carbamazepine (cbz) contribute to its widespreadand increasing use to control seizures in the epiletptic patients. however, in cases when oral drug treatment is notfeasible, no parenteral formulation is available for cbz. currently… More

PRODRUGS AND AQUEOUS FORMULATIONS OF DEXANABINOL

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Pop, emil
Abstract:
N/a